

Produktinformation



Forschungsprodukte & Biochemikalien
Zellkultur & Verbrauchsmaterial
Diagnostik & molekulare Diagnostik
Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien T. +43(0)1 489 3961-0 F. +43(0)1 489 3961-7 <u>mail@szabo-scandic.com</u> www.szabo-scandic.com

Colivelin TFA

®

MedChemExpress

Cat. No.:	HY-P1061A		
CAS No.:	2803948-60-7		
Molecular Formula:	C ₁₁₉ H ₂₀ 6N ₃₂ O ₃₅ .C ₂ HF ₃ O ₂		
Molecular Weight:	2759.12 SALLRSIPAPAGASRLLLLTGEIDLP (TFA salt)		
Sequence Shortening:	SALLRSIPAPAGASRLLLLTGEIDLP		
Target:	STAT; Amyloid-β; Apoptosis		
Pathway:	JAK/STAT Signaling; Stem Cell/Wnt; Neuronal Signaling; Apoptosis		
Storage:	Sealed storage, away from moisture		
	Powder -80°C 2 years		
	-20°C 1 year		
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)		

SOLVENT & SOLUBILITY

		Mass Solvent Concentration	1 mg	5 mg	10 mg	
	Preparing Stock Solutions	1 mM	0.3624 mL	1.8122 mL	3.6243 mL	
		5 mM	0.0725 mL	0.3624 mL	0.7249 mL	
		10 mM	0.0362 mL	0.1812 mL	0.3624 mL	
	Please refer to the so	Please refer to the solubility information to select the appropriate solvent.				
n Vivo		lubility information to select the app one by one: Water with 5% sefsol an				

BIOLOGICAL ACTIV	ИТҮ	
Description	Colivelin TFA is a brain penetrant neuroprotective peptide and a potent activator of STAT3, suppresses neuronal death by activating STAT3 in vitro ^[1] . Colivelin TFA exhibits long-term beneficial effects against neurotoxicity, Aβ deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease ^[2] . Colivelin TFA has the potential for the treatment of alzheimer's disease and ischemic brain injury ^[1] .	
IC ₅₀ & Target	STAT3	Amyloid-β
In Vitro	Colivelin completely suppresses death induced by overexpressed FAD-causative genes and Aβ1-43 at a concentration of 100 fm, and keep its neuroprotective action at or above the levels of 1 nm ^[1] . Colivelin-induced neuroprotection occurs via two neuroprotective pathways: one mediated by Ca ²⁺ /calmodulin-dependent protein kinase IV, triggered by ADNF, and one mediated by signal transducer and activator of transcription 3, triggered by HN	

Product Data Sheet

[1]

Colivelin reverses caspase3, Bax and Bcl-2 expressions in HT22 cells medaited by rmMFG-E8 in the co-cultured cells under OGD condition^[4].

Colivelin (50 µg/mL, 4 hours) significantly increases the p-STAT3 protein levels in BV-2 cells^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[4]

Cell Line:	BV-2 cells.
Concentration:	50 μg/mL.
Incubation Time:	4 hours.
Result:	Increased p-STAT3 levels.
Cell Viability Assay ^[5]	

Cell Line: KYSE70 and TE8 cells. Concentration: 0.5 μM. Incubation Time: 1 hour (followed by CYT-Rx20 treatment) Result: Significantly suppressed the viability in KYSE70 and TE8 cells.

In Vivo

Colivelin(intracerebroventricular administration; 10 pmol/3 μ l; 3 weeks) suppresses impairment in spatial working memory induced by repetitive intracerebroventricular injection of A β 25-35 or A β 1-42, in addition, it antagonizes neuronal loss in the CA1 region of hippocampus induced by hippocampal injection of A β 1-42^[1].

Colivelin (intraperitoneal administration; 1.4, 7, or 35 nM/0.21mL; on the Y-maze testday) suppresses memory impairment caused by 3-quinuclidinyl benzilateand restricts functional memory deficit^[1].

Colivelin (intraperitoneal injection; 1 mg/kg; 14 days) results in improved motor and cognitive function with time by performance of mNSS, rotarod, and corner turning test. It also reduces lesion volume and improves neurological deficits after MCAO^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	CD-1 mice ^[1]	
Dosage:	10 pmol/3 μl	
Administration:	Intracerebroventricular administration	
Result:	Completely suppressed Aß 25-35-mediated impairment in spatial working memory and increased the number of immunoreactive neurons.	
Animal Model:	C57 mice ^[1]	
Dosage:	1.4, 7, or 35 nM/0.21mL	
Administration:	Intraperitoneal administration	
Result:	Protected against cholinotoxin-induced amnesia in mice.	
Animal Model:	Male C57BL/6 mice ^[3]	

Dosage:	1 mg/kg
Administration:	Intraperitoneal administration
Result:	Protected against ischemic brain injury, and improves neurological outcomes.

CUSTOMER VALIDATION

- Sci Transl Med. 2021 Oct 6;13(614):eabg6428.
- Nat Commun. 2021 Nov 25;12(1):6891.
- Redox Biol. 2023 Nov 7, 102956.
- Proc Natl Acad Sci U S A. 2022 Oct 11;119(41):e2122099119.
- Int J Biol Sci. 2023 Mar.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Chiba T, et al. Development of a femtomolar-acting humanin derivative named colivelin by attaching activity-dependent neurotrophic factor to its N terminus: characterization of colivelin-mediated neuroprotection against Alzheimer's disease-relevant insults in vitro and in vivo. J Neurosci. 2005 Nov 2;25(44):10252-61.

[2]. Zhao H, et al. Colivelin Rescues Ischemic Neuron and Axons Involving JAK/STAT3 Signaling Pathway. Neuroscience. 2019 Sep 15;416:198-206.

[3]. Pan Z, et al. Upregulation of HSP72 attenuates tendon adhesion by regulating fibroblast proliferation and collagen production via blockade of the STAT3 signaling pathway. Cell Signal. 2020 Mar 18:109606.

[4]. Fang YY, et al. MFG-E8 alleviates oxygen-glucose deprivation-induced neuronal cell apoptosis by STAT3 regulating the selective polarization of microglia. Int J Neurosci. 2020 Mar 12:1-10.

[5]. Chiu WC, et al. The Synthetic β-Nitrostyrene Derivative CYT-Rx20 Inhibits Esophageal Tumor Growth and Metastasis via PI3K/AKT and STAT3 Pathways. PLoS One. 2016 Nov 22;11(11):e0166453.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA